Exploring the advantages of traditional Chinese medicine and dual-anti therapy for liver cirrhosis
10.3760/cma.j.cn501113-20250401-00115
- VernacularTitle:发扬中医药在肝硬化治疗中的优势：双抗治疗
- Author:
Yanqiu LI
1
;
Ying FENG
1
;
Xianbo WANG
1
;
Ke SHI
1
;
Yao LIU
1
;
Yao LIU
1
Author Information
1. 首都医科大学附属北京地坛医院中西医结合中心，北京 100015
- Publication Type:Journal Article
- Keywords:
Cirrhosis;
Traditional Chinese medicine and pharmacy;
Dual-anti therapy;
Anti-fibrosis therapy;
Antiviral therapy
- From:
Chinese Journal of Hepatology
2025;33(8):721-727
- CountryChina
- Language:Chinese
-
Abstract:
Liver cirrhosis is the terminal stage of chronic liver disease. Minimizing complications of liver cirrhosis and the occurrence of liver cancer has become an important goal for liver cirrhosis treatment. The primary etiology leading to liver cirrhosis is chronic hepatitis B infection. "Dual-anti therapy" refers to the combination of anti-viral and anti-fibrosis treatment, which is the characteristic and advantage of the integration of Chinese and Western medicine. The article elaborates on the concept and strategies of "dual antibody therapy" based on evidence-based medicine and introduces the research progress in terms of representative anti-fibrotic Chinese patent medicines for reversing liver cirrhosis, reducing the occurrence of hepatocellular carcinoma, and loweri ng portal hypertension and its complications and others, revealing that dual antibody therapy can clinically facilitate dual reduction" (reducing both liver cancer and complications of cirrhosis). Additionally, it analyzes and summarizes the mechanism of action of anti-fibrotic Chinese patent medicines and prospects of a new model of liver cirrhosis treatment combining Chinese and Western medicine, thereby providing novel ideas for the prevention and treatment of clinical liver diseases.
